Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).
Peg-IFN beta-1a
adherence
adverse event
multiple sclerosis
treatment satisfaction
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
12
2020
accepted:
26
02
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
Subcutaneous (SC) interferons beta (IFN-beta) are effective therapies for the treatment of relapsing-remitting multiple sclerosis (RRMS). Factors such as dosing schedule, needle intolerance/fatigue, and side effects may impact patient satisfaction with treatment. Improvement of patient satisfaction may increase the adherence to treatment and the patient quality of life. This study was aimed at evaluating the impact of switching to "Peginterferon beta-1a (Peg-IFN beta-1a)" in patients with RRMS unsatisfied with other SC interferons. The multicenter, open-label, phase IV PLATINUM study was conducted in 32 Italian centers. The primary endpoint was changes from baseline in the score of a convenience satisfaction domain of the TSQM-9 questionnaire at 12 weeks. The secondary endpoints were patients' global satisfaction, short-term adherence to treatment, satisfaction with the injection system, effect on fatigue, disease activity, and patient inability score. A total of 193 patients were enrolled and 166 (86%) completed the study, receiving Peg-IFN beta-1a for 24 weeks. Patients switching to Peg-IFN beta-1a from other SC interferons reported a significant improvement (
Identifiants
pubmed: 33967938
doi: 10.3389/fneur.2021.637615
pmc: PMC8101263
doi:
Types de publication
Journal Article
Langues
eng
Pagination
637615Informations de copyright
Copyright © 2021 Centonze, Fantozzi, Buttari, Grimaldi, Totaro, Corea, Marrosu, Confalonieri, Cottone, Trojano and Zipoli.
Déclaration de conflit d'intérêts
VZ was employed by the company Biogen Italy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Biogen Italia. The funder had the following involvement with the study: study design, data analysis, and revision of the manuscript.
Références
Mult Scler Relat Disord. 2017 Oct;17:107-115
pubmed: 29055438
Mult Scler Relat Disord. 2015 Jan;4(1):75-82
pubmed: 25787057
PLoS One. 2016 Aug 15;11(8):e0160313
pubmed: 27526201
J Manag Care Spec Pharm. 2017 Aug;23(8):844-852
pubmed: 28737986
Lancet. 2001 May 19;357(9268):1576-82
pubmed: 11377645
J Cyst Fibros. 2012 Dec;11(6):494-501
pubmed: 22583743
Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):702-711
pubmed: 28370875
Brain. 1999 Oct;122 ( Pt 10):1933-9
pubmed: 10506094
BMC Health Serv Res. 2020 Aug 26;20(1):797
pubmed: 32847587
Int J MS Care. 2014 Summer;16(2):68-75
pubmed: 25061430
N Engl J Med. 2000 Sep 28;343(13):898-904
pubmed: 11006365
Lancet Neurol. 2014 Jul;13(7):657-65
pubmed: 24794721
Eur J Neurol. 2011 Jan;18(1):69-77
pubmed: 20561039
Mult Scler Relat Disord. 2019 May;30:104-109
pubmed: 30763907
Patient Prefer Adherence. 2018 Apr 19;12:569-575
pubmed: 29720872
Patient Prefer Adherence. 2018 Jul 20;12:1289-1297
pubmed: 30050291
Health Qual Life Outcomes. 2004 Feb 26;2:12
pubmed: 14987333
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Neurology. 1996 Apr;46(4):907-11
pubmed: 8780061
J Nephrol. 2013 Mar-Apr;26(2):297-305
pubmed: 22684646
Health Qual Life Outcomes. 2009 Apr 27;7:36
pubmed: 19397800
Mult Scler. 2014 May;20(6):705-16
pubmed: 24126064
Acta Neurol Scand. 2006 Mar;113(3):156-62
pubmed: 16441244
Mult Scler Relat Disord. 2014 Sep;3(5):607-19
pubmed: 26265273